Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements review located that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid https://josephr975nqr6.blogsuperapp.com/profile